FDA actions and shortcomings | Print |  E-mail
Dr. Breggin’s educational campaigns and his scientific research contributed have put pressure on the FDA to change the contents of numerous FDA-approved labels for psychiatric drugs, including the neuroleptic (antipsychotic) drugs and the newer antidepressants.

Dr. Breggin’s articles about the FDA, especially the implications of recent label changes, can be found on this website in the section “The FDA: Articles, Critiques and Presentations .”
Dr. Breggin’s most complete analyses of the hand-in-glove relationships between the drug companies and the FDA can be found in the following three books:

Brain-Disabling Treatments in Psychiatry (2008)



Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision. Methods for safely withdrawing from psychiatric drugs are discussed in Dr. Breggin's new book, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients, and Their Families.